© 2021 Marker Therapeutics, Inc.
Marker Therapeutics will present at and participate in two upcoming investor conferences.
Marker Therapeutics reports Q1 earnings.
President and Chief Executive Officer, Peter L. Hoang, to present at the 2019 Bank of America Merrill Lynch Health Care Conference.
Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic hematopoietic cell transplantation (alloHCT) and subsequently relapsed.